Follow us on
  • Linkedin
  • Twitter
  • Facebook
  • Google+


  • 2012 08 21

    NEW at LSB2012: Innovative Medicines Initiatives' (IMI) Information Day on New Oppotunities For The Baltics

    The Innovative Medicines Initiative (IMI) is Europe's largest public-private partnership aiming to improve the drug development process by supporting a more efficient discovery and development of better and safer medicines for patients. IMI is a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA). FP7 contributes €1 billion to the IMI research programme, another €1 billion comes from member companies of EFPIA.

    IMI supports collaborative research projects and builds networks of industrial and academic experts in Europe that will boost innovation in healthcare. Acting as a neutral third party in creating innovative partnerships, the Initiative aims to build a more collaborative ecosystem for pharmaceutical research and development (R&D).

    IMI will provide socio-economic benefits to European citizens, increase Europe's competitiveness globally, and establish Europe as the most attractive place for pharmaceutical R&D.
    IMI supports research projects in the areas of safety and efficacy, knowledge management, and education and training. Projects are selected through open Calls for proposals.

    The target group: small and medium-sized enterprises, patients' organizations, universities and other research organizations, hospitals, regulatory agencies and any other industrial partners.

    Prof. Michael Goldman, Executive Director of the Innovative Medicines Initiative (IMI), will present the key objectives of the initiative and basic participation rules, ongoing IMI projects and future calls for proposals, as well as practical aspects on how to submit a successful proposal.

    The Information Day will take place in Vilnius, Lithuania, at hotel Le Méridien's Grand Opera Hall (Highway A2, 19th km), on the 14th of September, 9 AM - 12 PM.

    Registration is open till the 11th
    of September by telephone +370 85 2644 711, or by e-mail: